Given their central role, microglia have emerged as promising therapeutic targets in AD, with novel strategies including TREM2 agonists [11, 12], anti-inflammatory modulation [13, 14], and gene-editing approaches [15, 16]. This evidence concerns the gene TREM2 and Alzheimer disease.